The information contained in this offering circular includes some statements that are not historical and that are considered forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding our development plans for our business; our strategies and business outlook; anticipated development of our company; and various other matters (including contingent liabilities and obligations and changes in accounting policies, standards and interpretations). These forward-looking statements express our expectations, hopes, beliefs and intentions regarding the future. In addition, without limiting the foregoing, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words anticipate, believe, continue, could, estimates, expects, intends, may, might, plans, possible, potential, predicts, projects, seeks, should, will, would and similar expressions and variations, or comparable terminology, or the negatives of any of the foregoing, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this offering circular are based on current expectations and beliefs concerning future developments that are difficult to predict. We cannot guarantee future performance, or that future developments affecting our company will be as currently anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

All forward-looking statements attributed to us are expressly qualified in their entirety by these risks and uncertainties. These risks and uncertainties, along with others, are also described below in the Risk Factors section. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on any forward-looking statements and should not make an investment decision based solely on these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

7

Some of the statements under “Summary”, “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, “Our Business” and elsewhere in this Offering Circular constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “should”, “will” and “would” or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Offering Circular, including in “Risk Factors” and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors are included, among other things:

·The speculative nature of the business we intend to develop; 

·Our ability to source potential acquisitions 

·Our dependence upon external sources for the financing of our operations; 

·Our ability to effectively execute our business plan; 

·Our ability to manage our expansion, growth and operating expenses; 

·Our ability to finance our businesses; 

·Our ability to promote our businesses; 

·Our ability to compete and succeed in a highly competitive and evolving businesses environment; 

·Our ability to protect our intellectual property and to develop, maintain and enhance strong brands. 

Although the forward-looking statements in this Offering Circular are based on our beliefs, assumptions and expectations, considering all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as maybe be required by law, to re-issue this Offering Circular or otherwise make public statements updating our forward-looking statements.

The following summary highlights material information contained in this offering circular. This summary does not contain all of the information you should consider before purchasing our common stock. Before making an investment decision, you should read this offering circular carefully, including the Risk Factors section and the unaudited consolidated financial statements and the notes thereto. Unless otherwise indicated, the terms we, us and our refer and relate to Blockhold Capital Corporation, a Nevada corporation, including its wholly owned subsidiaries: Virtual Clinic, LLC, an Indiana LLC, Telecare Holdings, Inc., a Wyoming corporation, Sanologics, Inc, a Wyoming corporation and Sneeze Free Living (TM pending).

Our Company

The Company was incorporated in the State of Nevada on October 1, 2010, under the name Moms Online, Inc. (“Moms Online”). Moms Online was formed as a wholly owned subsidiary of Ice Lounge Media, Inc. (“ICE”) to hold, create, collect and adapt social media site aimed at mothers.

ICE spun out Moms Online to the ICE shareholders in late 2013 to further the ongoing focus of Moms Online on the continued development of websites devoted to moms and to reduce the dual funding obligations of ICE and Moms Online. The spin off was accomplished through a share dividend from ICE to its shareholders. Following the spin-off, ICE retained 50% of the Company while the other 50% was held by the 41 original shareholders of ICE.

8

On September 25, 2014, the Company filed Form 10 which was deemed effective on January 23, 2015. The Company received its symbol (“MOMC”) from FINRA on September 10, 2015. Even though the Company is public, none of its shares have traded publicly as of this date.  On March 12, 2018, the Company entered into a share exchange agreement with BlockHold Capital, Inc. (“BlockHold”) whereby the Company acquired all the shares of BlockHold and issued 28,000,000 shares of the Company to the BlockHold shareholders representing approximately 85% of the outstanding shares of the Company. To properly disclose the details of the transaction the Company filed a Form 8-K statement on March 16, 2018. The Company also filed Form SC 14F1 Information of change in directors on March 23, 2018. The Company’s Board of Directors approved a change of its name to Blockhold Capital Corporation that was effective on April 17, 2018, to better reflect the focus of its business activities in the development of blockchain related solutions. Both the CUSIP number and the trading symbol for the common stock of the company were changed.  The Company on August 30, 2019, entered into a Settlement Agreement to rescind the above agreement. The shares issued were returned to the Treasury, certain releases were entered into, there was a change in directors and $52,250 was paid to the above parties. The Settlement Agreement transaction returned everything to the original status of the Company before the share exchange. Additionally, the Company paid $20,000 in attorney fees. A litigation loss was recorded in 2019 in the amount of $72,250 which represented the above amounts paid regarding this matter.

Our principal executive offices are located at 3226 Clark Rd., Sarasota, FL, 34231, and our telephone number is (502) 295-7424. We maintain a website at www.telecareholdings.com. Information contained on or accessible through our website is not, and should not be considered, part of, or incorporated by reference into, this offering circular.

The Offering

This Offering is a self-underwritten offering, which means that it does not involve the participation of an underwriter to the market. Our Offering Price is arbitrary with no relation to the value of the Company.

9

RISK FACTORS

An investment in our common stock is highly speculative and involves a high degree of risk. The risk factors described below summarize some of the material risks inherent in an investment in us. These risk factors are not presented in any particular order of significance. Each prospective investor should carefully consider the following risk factors inherent in and affecting our business and the Offering before making an investment decision. You should also refer to the other information set forth in this Offering Circular and to the risk factors in our SEC filings.

Risks Relating to our Financial Condition

We are a company with a limited operating history and have not generated significant revenues to date. We may never generate significant revenues.  We have incurred losses since our inception. As of June 30, 2024, we had a total accumulated deficit of $3,287,648. While we have begun to realize revenues from Virtual Clinic LLC, these revenues have shown increases over the past two years, but profitability and cash flow have been minimal. Accordingly, it is impossible for us meaningfully to project the revenue levels that might be achieved or whether and when we might become profitable. In order to increase the market for our services and to capitalize on the potential of our intellectual property, we must conduct certain marketing campaigns, obtain certain approvals for other products we are currently seeking to sell and seek recognition of our products within the healthcare industry including third party payors. We must also attract, retain, and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so could lead to an inability to meet our financial obligations and therefore result in bankruptcy and the loss of your entire investment in our common shares.

Our internal controls are not effective, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public. Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

We currently have a limited executive management group managing the financial controls of the Company. We have certain management personnel who operate under consulting contracts on a part-time basis, who are responsible for monitoring and ensuring compliance with our internal control procedures. As a result, our internal controls may be inadequate or ineffective, which could cause our financial reports to be unreliable and lead to misinformation being disseminated to the public. Investors relying upon the reporting may make an uninformed investment decision.

Risks Relating to our Present Business and our Present Industry

We have incurred losses in prior periods, and losses in the future could cause the quoted price of our common stock to decline or have a material adverse effect on our financial condition, our ability to pay our debts as they become due, and on our cash flows. We have incurred losses in prior periods. For the nine months ending September 30, 2025, we incurred a net loss of $211,197 and an accumulated deficit of $3,582,710. For the year ended December 31, 2024, we incurred a net loss of $352,120 (audited) and, as of that date, we had an accumulated deficit of $3,571,394 (audited). For the year ended December 31, 2023, we incurred a net loss of $270,669 (audited) and, as of that date, we had an accumulated deficit of $3,219,274 (audited). Any losses in the future could cause the quoted price of our common stock to decline or have a material adverse effect on our financial condition, our ability to pay our debts as they become due, and on our cash flows.

There is doubt about our ability to continue as a viable business. We have not earned a profit from our operations during recent financial periods. There is no assurance that we will ever earn a profit from our operations in future financial periods.

10

We may be unable to obtain sufficient capital to implement our full plan of business. Currently, we do not have sufficient financial resources with which to establish our new business strategies. There is no assurance that we will be able to obtain sources of financing, including in this offering, in order to satisfy our working capital needs.

There are risks and uncertainties encountered by under-capitalized companies. As an under-capitalized company, we are unable to offer assurance that we will be able to overcome our lack of capital, among other challenges.

We may never earn a profit in future financial periods. Because we lack a successful operating history, we are unable to offer assurance that we will ever earn a profit in future financial periods.

If we are unable to manage future expansion effectively, our business may be adversely impacted. In the future, we may experience rapid growth in our operations, which could place a significant strain on our company’s infrastructure, in general, and our internal controls and other managerial, operating and financial resources, in particular. If we are unable to manage future expansion effectively, our business will be harmed. There is, of course, no assurance that we will enjoy rapid development in our business.

If we are unable to recruit and retain key personnel, our business may be harmed. If we are unable to attract and retain key personnel, our business may be harmed. Our failure to enable the effective transfer of knowledge and facilitate smooth transitions with regard to our key employees could adversely affect our long-term strategic planning and execution.

Our newly implemented marketing strategies are not based on independent market studies. We have not commissioned any independent market studies with respect to the health supplement industry. Rather, our plans for implementing our aviation services and achieving profitability are based on the experience, judgment and assumptions of our management. If these assumptions prove to be incorrect, we may not be successful in expanding sales of our health products.

Our Board of Directors may change our policies without shareholder approval. Our policies, including any policies with respect to investments, leverage, financing, growth, debt and capitalization, will be determined by our Board of Directors or officers to whom our Board of Directors delegates such authority. Our Board of Directors will also establish the amount of any dividends or other distributions that we may pay to our shareholders. Our Board of Directors or officers to which such decisions are made will have the ability to amend or revise these and our other policies at any time without shareholder vote. Accordingly, our shareholders will not be entitled to approve changes in our policies, which policy changes may have a material adverse effect on our financial condition and results of operations.

We may encounter numerous difficulties frequently encountered by companies in the early stage of operations. We have a limited operating history upon which an investor can evaluate our current business and future prospects. Any potential investor must consider the risks and difficulties frequently encountered by early-stage companies. Historically, there has been a high failure rate among early-stage companies. Our future performance will depend upon a number of factors, including our ability to:

·generate revenues and implement our business plan and growth strategy; 

·attract and retain marketing and commercial sponsors; 

·aggressively counter and respond to actions by our competitors; 

·maintain adequate control of our expenses; 

·attract, retain and motivate qualified personnel; 

·react to member preferences and demands; 

·maintain regulatory compliance; and 

·generate sufficient working capital through our operations or through issuance of additional debt or equity financing, and to continue as a going concern. 

We cannot assure investors that we will successfully address any of these factors, and our failure to do so could have a material adverse effect on our business, financial condition, results of operations and future prospects.

The loss of the services of our key management and personnel or the failure to attract additional key personnel could adversely affect our ability to operate our business. The loss of one or more of our current officers or key employees or consultants could severely and negatively impact our operations. We have no present intention of

11

obtaining key-man life insurance on any of our executive officers or management. Additionally, competition for highly skilled technical, managerial and other personnel is intense. As our business develops, we might not be able to attract, hire, train, retain and motivate the highly skilled managers and employees we need to be successful. If we fail to attract and retain the necessary technical and managerial personnel, our business will suffer and might fail.

Our limited operating history could delay our growth and result in the loss of your investment. We were incorporated on October 1, 2010. However, our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their growth stage of development. Such risks include, but are not limited to, dependence on the growth of use of technology and services, complete product development, marketing analysis and obtain industry acceptance while responding to competitive developments and attracting, retaining, and motivating qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so could lead to an inability to meet our financial obligations and therefore result in bankruptcy and the loss of your entire investment in our common shares. In July 2021 we acquired Virtual Clinic, LLC.  However, we will be required to allocate our limited resources effectively to complete the required market analysis and enter into other contracts with our vendors and obtain market acceptance for the products we currently sell.

Our ability to implement and manage growth strategies is uncertain. We plan on expanding the market segments in which we currently have assets allocated.  We anticipate further merger and acquisition activity to facilitate growth.    Failure by the Company to manage its growth, or unexpected difficulties encountered during expansion into different markets, could have a materially adverse impact on our results of operations or financial condition. Our ability to continue to operate our business depends upon a number of factors, including (i) generating sufficient funds for operations, (ii) our executive management team and our financial and accounting controls, and (iii) staffing, training, and retaining skilled on-site management personnel. Certain these factors are beyond our control and may be affected by the economy or actions taken by competing companies. Further, there can be no assurance that our market analysis and proprietary business data will continue to support our current marketing plans.

We may not be able to retain our key personnel or attract additional personnel, which could affect our ability to complete necessary clinical trials and obtain approvals so that we can generate sufficient revenue to continue as a going concern diminishing your return on investment. Our performance is substantially dependent on the services and on the performance of our Management. Blockhold is, and will be, heavily dependent on the skill, acumen and services of our key executives. Our performance also depends on our ability to attract, hire, retain and motivate our officers and key employees. The loss of the services of our executives could result in lost revenue depending on the length of time and effort required to find qualified replacements. We have not entered into long-term employment agreements with all of our key personnel and currently have no “Key Employee” life insurance policies.

Our future success may also depend on our ability to identify, attract, hire, train, retain and motivate other highly skilled technical, managerial, marketing, sales and customer service personnel. Competition for such personnel is intense, and there can be no assurance that we will be able to successfully attract, assimilate or retain sufficiently qualified personnel. If we are unable to attract, retain, and train the necessary technical, managerial, marketing and customer service personnel, our expectations of increasing our clientele could be hindered, and the profitability of Blockhold reduced.

The Company may not be successful in developing and implementing policies and strategies to address the foregoing factors in a timely and effective manner in the locations where it will do business. Consequently, the occurrence of one or more of the foregoing factors could have a material adverse effect on its base operations and upon its financial condition and results of operations.

We may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome. Our business relies in large part on intellectual property which we possess. However, the ownership/possession does not ensure that litigation will not arise where the validity of the intellectual property is challenged or that the property will not be found by a court to infringe upon property held by others. Furthermore, any litigation relating to our property rights is likely to be expensive and may require a significant amount of management’s time and attention, at the expense of other aspects of our business. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business and financial condition.

We may not be able to obtain third-party reimbursement or favorable product pricing, margin which would reduce our ability to operate profitably. Our ability to successfully commercialize certain of our proposed products may depend to a significant degree on reimbursement of the costs of such products and related services at acceptable levels

12

from government authorities and other organizations. We cannot assure you that reimbursement in the United States or foreign countries will be available for any products we may develop or, if available, will not be decreased in the future, or that reimbursement amounts will not reduce the demand for, or the price of, our products with a consequent harm to our business. We cannot predict what additional regulation or legislation may be enacted in the future or what effect such regulation or legislation may have on our business. If additional regulations are overly onerous or expensive, making our business more expensive or burdensome than originally anticipated, we may be forced to significantly downsize our business plans or completely abandon our business model.

We have not adopted various corporate governance measures, and as a result, stockholders may have limited protection against interested director transactions, conflicts of interest and similar matters. Federal legislation, including the Sarbanes-Oxley Act of 2002, has resulted in the adoption of various corporate governance measures designed to promote the integrity of corporate management and the securities markets. Because our securities are not yet listed on a national securities exchange, we are not required to adopt these corporate governance measures and have not done so voluntarily in order to avoid incurring the additional costs associated with such measures. Furthermore, the absence of the governance measures referred to above with respect to our Company may leave our stockholders with more limited protection in connection with interested director transactions, conflicts of interest and similar matters.

Certain provisions of Nevada law applicable to Blockhold could also delay a merger, tender offer, or proxy contest or make one more difficult. As a Nevada corporation, we are subject to Nevada law, including Section 203 of the Nevada General Corporation Law. In general, Section 203 prohibits Nevada corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section 203. These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.

If our products do not provide the healthful effects intended, our business may suffer. In general, our products contain food, vitamins, minerals and nutritional supplements which are classified in the United States as “dietary supplements” and do not currently require approval from the FDA or other regulatory agencies prior to sale. Many of our products contain innovative ingredients or combinations of ingredients. There is little long-term experience with human or other animal consumption of certain of these ingredients or combinations thereof in concentrated form. Our products could have certain side effects if not taken as directed or if taken by a consumer that has certain medical conditions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects.

Our marketing strategies for our products may not be successful. We will be required to obtain a significantly greater number of customers for our health products, in order to increase sales. Should our newly implemented marketing strategies fail to increase sales of our health products, our operations will be adversely affected.

Our success will depend on external factors in the nutritional and dietary supplement industries. The success of our current and planned products is highly unpredictable, and success depends on identifying and reaching ever evolving consumer tastes and desires. The commercial success of a nutritional supplement also depends upon:

·the quality and acceptance of other competing brands and products; 

·creating effective distribution channels and brand awareness; 

·critical reviews; 

·the availability of alternatives; 

·general economic conditions; and 

·other tangible and intangible factors. 

The scientific support for our products is subject to uncertainty. Our research, scientific knowledge and clinical testing supporting the nutritional benefits of our products is an essential element of our ability to legally market our products. We believe that our own findings, the results of the third-party studies performed, and our research are sound and that we have a reasonable basis to rely on them in marketing our products. There is, however, the risk that new or undiscovered information may become available that may undermine or refute our scientific support. A reduction in the credibility of our scientific support for the nutritional benefits of our products could have a material adverse effect on our operations and financial conditions.

13

As our business expands, the number of products and competitors in our markets increases and product overlaps occur, and infringement claims may increase in number and significance. Intellectual property lawsuits are subject to inherent uncertainties due to the complexity of the technical issues involved, and we cannot be certain that we would be successful in defending ourselves against intellectual property claims. Further, many potential litigants have the capability to dedicate substantially greater resources than we can to enforce their intellectual property rights and to defend claims that may be brought against them. Furthermore, a successful claimant could secure a judgment that requires us to pay substantial damages or prevents us from distributing products or performing certain services.

If we fail to develop our brand names cost-effectively, our business may be adversely affected. The success of our products marketed under our brand names depends upon the effectiveness of our marketing efforts. Brand promotional activities may not yield increased revenue, and even if they do, any increased revenue may not offset the expenses incurred in building the brands. If we fail to successfully promote and maintain our brands or incur substantial expenses in an unsuccessful attempt to promote and maintain our brands, we may fail to attract enough new customers or retain our existing customers to the extent necessary to realize a sufficient return on our brand-building efforts, and our business and results of operations could suffer.

The purchase of our products is discretionary and may be negatively impacted by adverse trends in the general economy which would make it more difficult for us to sell our products. Our business is affected by general economic conditions since our products are discretionary and we depend, to a significant extent, upon a number of factors relating to discretionary consumer spending. These factors include economic conditions and perceptions of such conditions by consumers, employment rates, level of consumers’ disposable income, business conditions, interest rates, consumer debt levels and availability of credit. Consumer spending on our products may be adversely affected by changes in general economic conditions.

The success of our business depends on our ability to market and advertise our Companies effectively. Our ability to establish effective marketing and advertising campaigns is the key to our success. Our advertisements promote our corporate image, our dietary and nutritional products and the pricing of such products. If we are unable to increase awareness of our brands and our products, we may not be able to attract new distributors for our products. Our marketing activities may not be successful in promoting the products we sell or pricing strategies or in retaining and increasing our distributor base. We cannot assure you that our marketing programs will be adequate to support our future growth, which may result in a material adverse effect on our results of operations.

We face uncertainty and costly compliance with government regulations. The manufacturing, processing, formulating, packaging, labeling, distributing, selling and advertising of our products are subject to regulation by one or more federal agencies. The most active regulation has been administered by The Food and Drug Administration (hereinafter the “FDA”) which regulates our products pursuant to the Federal Food, Drug and Cosmetic Act (hereinafter the “FDCA”) and regulations promulgated thereunder. In particular, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements, including vitamins, minerals and herbs, food additives, food supplements, over-the-counter drugs and prescription drugs, medical devices and cosmetics. In addition, the Federal Trade Commission (hereinafter the “FTC”) has overlapping jurisdiction with the FDA to regulate the labeling, promotion and advertising of dietary supplements, over the counter drugs, cosmetics and foods.

Compliance with applicable FDA and any state or local statute is critical. Although we believe that we will follow applicable statutes, there can be no assurance that should the FDA amend its guidelines or impose more stringent interpretations of current laws or regulations, we would be able to comply with these new guidelines. We are unable to predict the nature of such future laws, regulations, interpretations or applications, nor can we predict what effect additional governmental regulations or administrative orders, when and if promulgated, would have on our business in the future. These regulations could, however, require the reformation of our products to meet new standards, market withdrawal or discontinuation of certain products not able to be reformulated.

Risks Relating to Our Reliance on Third Parties

Because our Business Involves Medical Products, Our Business Tends to be Capital Intensive. We are likely to require additional capital to maintain operations or expand our business. We have not made any arrangements to obtain any additional financing. Any additional financing may only be available on terms unfavorable to us and disadvantageous to our shareholders.

The Protection from our Future Technology is Uncertain. We will rely on our intellectual property, products and trade secrets for the protection of our business activities. The possession and ownership do not ensure that the

14

intellectual property will be upheld if it is challenged in litigation or that the marketing strategies and the underlying products will not be found to infringe upon other technologies validly possessed by others. We could be exposed to substantial litigation expenses defending their intellectual property as well as liability to others.

Risks Related to Compliance and Regulation

We will not have reporting obligations under Sections 14 or 16 of the Securities Exchange Act of 1934, nor will any shareholders have reporting requirements of Regulation 13D or 13G, nor Regulation 14D. So long as our common shares are not registered under the Exchange Act, our directors and executive officers and beneficial holders of 10% or more of our outstanding common shares will not be subject to Section 16 of the Exchange Act. Section 16(a) of the Exchange Act requires executive officers and directors and people who beneficially own more than 10% of a registered class of equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of common shares and other equity securities, on Forms 3, 4 and 5, respectively.

Our common stock is not registered under the Exchange Act and we do not intend to register our common stock under the Exchange Act for the foreseeable future; provided, however, that we will register our common stock under the Exchange Act if we have, after the last day of any fiscal year, more than either (1) 2,000 persons; or (2) 500 shareholders of record who are not accredited investors, in accordance with Section 12(g) of the Exchange Act.

Further, as long as our common stock is not registered under the Exchange Act, we will not be subject to Section 14 of the Exchange Act, which, among other things, prohibits companies that have securities registered under the Exchange Act from soliciting proxies or consents from shareholders without furnishing to shareholders and filing with the SEC a proxy statement and form of proxy complying with the proxy rules.

The reporting required by Section 14(d) of the Exchange Act provides information to the public about people other than the company who is making the tender offer. A tender offer is a broad solicitation by a company or a third party to purchase a substantial percentage of a company’s common stock for a limited period of time. This offer is for a fixed price, usually at a premium over the current market price, and is customarily contingent on shareholders tendering a fixed number of their shares.

In addition, as long as our common stock is not registered under the Exchange Act, our company will not be subject to the reporting requirements of Regulation 13D and Regulation 13G, which require the disclosure of any person who, after acquiring directly or indirectly the beneficial ownership of any equity securities of a class, becomes, directly or indirectly, the beneficial owner of more than 5% of the class.

There may be deficiencies with our internal controls that require improvements. Our company is not required to provide a report on the effectiveness of our internal controls over financial reporting. We are in the process of evaluating whether our internal control procedures are effective and, therefore, there is a greater likelihood of undiscovered errors in our internal controls or reported financial statements as compared to issuers that have conducted such independent evaluations.

Risks Related to Our Organization and Structure

As a non-listed company conducting an exempt offer pursuant to Regulation A, we are not subject to a number of corporate governance requirements, including the requirements for independent board members. As a non-listed company conducting an exempt offer pursuant to Regulation A, we are not subject to a number of corporate governance requirements that an issuer conducting an offering on Form S-1 or listing on a national stock exchange would be. Accordingly, we are not required to have (a) a board of directors of which a majority consists of independent directors under the listing standards of a national stock exchange, (b) an audit committee composed entirely of independent directors and a written audit committee charter meeting a national stock exchange’s requirements, (c) a nominating/corporate governance committee composed entirely of independent directors and a written nominating/ corporate governance committee charter meeting a national stock exchange’s requirements, (d) a compensation committee composed entirely of independent directors and a written compensation committee charter meeting the requirements of a national stock exchange, and (e) independent audits of our internal controls. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of a national stock exchange.

15

Our holding company structure makes us dependent on our subsidiaries for our cash flow and could serve to subordinate the rights of our shareholders to the rights of creditors of our subsidiaries, in the event of insolvency or liquidation of any such subsidiary. Our company acts as a holding company and, accordingly, substantially all of our operations are conducted through our subsidiaries. Such subsidiaries will be separate and distinct legal entities. As a result, substantially all of our cash flow will depend upon the earnings of our subsidiaries. In addition, we will depend on the distribution of earnings, loans or other payments by our subsidiaries. No subsidiary will have any obligation to provide our company with funds for our payment obligations. If there is an insolvency, liquidation or other reorganization of any of our subsidiaries, our shareholders will have no right to proceed against their assets. Creditors of those subsidiaries will be entitled to payment in full of the sale or other disposal of the assets of those subsidiaries before our company, as a shareholder, would be entitled to receive any distribution from that sale or disposal.

There is no minimum offering, and no person has committed to purchase any of the Shares. We have not established a minimum offering hereunder, which means that we will be able to accept even a nominal amount of proceeds, even if such an amount of proceeds is not sufficient to permit us to achieve any of our business objectives. In this regard, there is no assurance that we will sell any of the Shares or that we will sell enough of the Shares necessary to achieve any of our business objectives. Additionally, no person is committed to purchasing any of the Shares.

We may seek additional capital that may result in shareholder dilution or that may have rights senior to those of our common stock. From time to time, we may seek to obtain additional capital, either through equity, equity-linked or debt securities. The decision to obtain additional capital will depend on, among other factors, our business plans, operating performance and the condition of the capital markets. If we raise additional funds through the issuance of equity, equity-linked or debt securities, those securities may have rights, preferences or privileges senior to the rights of our common stock, which could negatively affect the market price of our common stock or cause our shareholders to experience dilution.

You may never realize any economic benefit from the purchase of Shares. Because the market for our common stock is volatile, there is no assurance that you will ever realize any economic benefit from your purchase of Shares.

We do not intend to pay dividends on our common stock. We intend to retain earnings, if any, to provide funds for the implementation of our business strategy. We do not intend to declare or pay any dividends in the foreseeable future. Therefore, there can be no assurance that holders of our common stock will receive cash, stock or other dividends on their shares of our common stock, until we have funds which our Board of Directors determines can be allocated to dividends.

Our shares of common stock are Penny Stock, which may impair trading liquidity. Disclosure requirements pertaining to penny stocks may reduce the level of trading activity in the market for our common stock and investors may find it difficult to sell their shares. Trades of our common stock will be subject to Rule 15g-9 of the SEC, which rule imposes certain requirements on broker-dealers who sell securities subject to the rule to people other than established customers and accredited investors. For transactions covered by the rule, broker-dealers must make a special suitability determination for purchasers of the securities and receive the purchaser’s written agreement to the transaction prior to sale. The SEC also has rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in that security is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with a current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation.

Our common stock is thinly traded, and its market price may become highly volatile. There is currently only a limited market for our common stock. A limited market is characterized by a relatively limited number of shares in the public float, relatively low trading volume and a small number of brokerage firms acting as market makers. The market for low priced securities is generally less liquid and more volatile than securities traded on national stock markets. Wide fluctuations in market prices are not uncommon. No assurance can be given that the market for our common stock

16

will continue. The price of our common stock may be subject to wide fluctuations in response to factors such as the following, some of which are beyond our control:

·quarterly variations in our operating results; 

·operating results that vary from the expectations of investors; 

·changes in expectations as to our future financial performance, including financial estimates by investors; 

·reaction to our periodic filings, or presentations by executives at investor and industry conferences; 

·changes in our capital structure; 

·announcements of innovations or new services by us or our competitors; 

·announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures 

·or capital commitments; 

·lack of success in the expansion of our business operations; 

·announcements by third parties of significant claims or proceedings against our company or adverse developments 

·in pending proceedings; 

·additions or departures of key personnel; 

·asset impairment; 

·temporary or permanent inability to offer products or services; and 

·rumors or public speculation about any of the above factors. 

The terms of this offer were determined arbitrarily. The terms of this offering were determined arbitrarily by us. The offering price for the Shares does not necessarily bear any relationship to our company’s assets, book value, earnings or other established criteria of valuation. Accordingly, the offering price of the Shares should not be considered as an indication of any intrinsic value of such securities. (See “Dilution”).

Our common stock is subject to price volatility unrelated to our operations. The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our company’s competitors or our company itself. In addition, the over-the-counter stock market is subject to extreme price and volume fluctuations in general. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.

Future sales of our common stock, or the perception in the public markets that these sales may occur, could reduce the market price of our common stock. In general, our officers and directors and major shareholders, as affiliates, under Rule 144 may not sell more than one percent of the total issued and outstanding shares in any 90-day period and must resell the shares in an unsolicited brokerage transaction at the market price. The availability for sale of substantial amounts of our common stock under Rule 144 or otherwise could reduce prevailing market prices for our common stock.

You will suffer dilution in the net tangible book value of the Shares you purchase in this offering. If you acquire any Shares, you will suffer immediate dilution, due to the lower book value per share of our common stock compared to the purchase price of the Shares in this offering. (See “Dilution”).

As an issuer of penny stock, the protection provided by the federal securities laws relating to forward looking statements does not apply to us. Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to issuers of penny stocks. As a result, we will not have the benefit of this safe harbor protection in the event of any legal action based upon a claim that the material provided by us contained a material misstatement of fact or was misleading in any material respect because of our failure to include any statements necessary to make the statements not misleading. Such an action could hurt our financial condition.

Risks Relating to our Offering

In order to raise sufficient funds to expand our operations, we may have to issue additional securities at prices which may result in substantial dilution to our shareholders. If we raise additional funds through the sale of equity

17

or convertible debt, our current stockholders’ percentage ownership will be reduced. In addition, these transactions may dilute the value of our common shares’ outstanding. We may also have to issue securities that may have rights, preferences and privileges senior to our Common Stock.

Currently, there is no public market for our securities, and there can be no assurances that any public market will ever develop and, even if developed, it is likely to be subject to significant price fluctuations. We do not have a trading symbol for our Common Stock. Consequently, there can be no assurances as to whether:

·any market for our shares will develop; 

·the prices at which our Common Stock will trade; or 

·The extent to which investor interest in us will lead to the development of an active, liquid trading market. 

Active trading markets generally result in lower price volatility and more efficient execution of buy and sell orders for investors.

Until our Common Stock is fully distributed and an orderly market develops in our Common Stock, if ever, the price at which it trades is likely to fluctuate significantly. Prices for our Common Stock will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity of the market for shares of our Common Stock, developments affecting our business, including the impact of the factors referred to elsewhere in these risk factors, investor perception of our company and general economic and market conditions. No assurances can be given that an orderly or liquid market will ever develop for the shares of our Common Stock.

Since we intend to retain any earnings for the development of our business for the foreseeable future, you will likely not receive any dividends for the foreseeable future. We have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future.

We will require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all. We intend to continue to make investments to support our business growth and may require additional funds to respond to business challenges, including the need to update our technology, improve our operating infrastructure or acquire complementary businesses and technologies. Accordingly, we will need to engage in continued equity or debt financing to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of our Common Stock.

Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

Additional capital may not be available on favorable terms, or at all, which could compromise our ability to meet our financial obligations and grow our business. Additional capital may also dilute your ownership. We expect that we will need to raise additional capital in the immediate future to fund our operations and acquisition strategy. We continue to seek capital from a variety of sources to meet our objectives, including launching our products, developing future products, increasing working capital and responding to competitive pressures; however, future capital may not be available on favorable terms or may not be available at all. Lack of sufficient capital resources could significantly limit our ability to take advantage of business and strategic opportunities. Any additional capital raised through the sale of equity or debt securities with an equity component will dilute the ownership of our stockholders. If adequate additional funds are not available, we may be required to delay, reduce the scope of, or eliminate, material parts of our business strategy, including research and development activities for our medical procedures.

You will experience dilution. The offering price is substantially higher than the pro forma net tangible book value per share of our Common Stock immediately following this offering based on the total value of our tangible assets less our total liabilities. Therefore, if you purchase shares of our Common Stock in this offering, based on the offering price of $1.50 per share, you will experience immediate dilution equal to the difference between the price per share you pay for our Common Stock and its pro forma net tangible book value per share as of September 30, 2025, after

18

giving effect to the issuance of shares of our Common Stock in this offering and assuming that the maximum number of shares are sold in this Offering. In addition, upon the completion of this offer, there will be options to purchase shares of our Common Stock outstanding, based on the number of such awards outstanding on. To the extent shares of Common Stock shares are issued with respect to such awards in the future, there will be further dilution to new investors.

There is no minimum offering. We have elected to proceed with no minimum amount of funds raised in this offering. Consequently, we will proceed with whatever funds are available. All funds will be immediately available to the Company. There is no assurance that such funds will be sufficient to successfully operate. Risk will be proportionally increased. Further, the less funds that are raised, the greater the dilution that will be faced by the investors in this offering. See “Dilution.”

Non-FDA Government Regulation May Affect our Results. The advertising of our products will be subject to both FDA and Federal Trade Commission regulations. In addition, the sale and marketing of our devices will be subject to a complex system of federal and state laws and regulations intended to deter, detect, and respond to fraud and abuse in the healthcare system. These laws and regulations restrict and may prohibit pricing, discounting, commissions and other commercial practices that may be typical outside of the healthcare business. In particular, anti-kickback and self-referral laws and regulations will limit our flexibility in crafting promotional programs and other financial arrangements in connection with the sale of our products and related services, especially with respect to physicians seeking reimbursement through Medicare or Medicaid. These federal laws include, by way of example, the following:

·The anti-kickback statute prohibits certain business practices and relationships that might affect the provision and cost of healthcare services reimbursable under Medicare, Medicaid and other federal healthcare programs, including the payment or receipt of remuneration for the referral of patients whose care will be paid by Medicare or other federal healthcare programs; 

·the physician self-referral prohibition, commonly referred to as the Stark Law, which prohibits referrals by physicians of Medicare or Medicaid patients to providers of a broad range of designated healthcare services in which the physicians or their immediate family members have ownership interests or with which they have certain other financial arrangements; 

·the anti-inducement law, which prohibits providers from offering anything to Medicare or Medicaid beneficiary to induce that beneficiary to use items or services covered by either program; 

·the Civil False Claims Act, which prohibits any person from knowingly presenting or causing to be presented false or fraudulent claims for payment by the federal government, including the Medicare and Medicaid programs; and 

·the Civil Monetary Penalties Law, which authorizes the US Department of Health and Human Services (“HHS”) to impose civil penalties administratively for fraudulent or abusive acts. 

Sanctions for violating these federal laws include criminal and civil penalties that range from punitive sanctions, damage assessments, money penalties, imprisonment, denial of Medicare and Medicaid payments, or exclusion from the Medicare and Medicaid programs, or both. These laws also impose an affirmative duty on those receiving Medicare or Medicaid funding to ensure that they do not employ or contract with people excluded from the Medicare and other government programs.

Many states have adopted or are considering legislative proposals similar to the federal fraud and abuse laws, some of which extend beyond the Medicare and Medicaid programs to prohibit the payment or receipt of remuneration for the referral of patients and physician self-referrals regardless of whether the service was reimbursed by Medicare or Medicaid. Many states have also adopted or are considering legislative proposals to increase patient protection, such as limiting the use and disclosure of patient-specific health information. These state laws typically impose criminal and civil penalties similar to the federal laws.

In the ordinary course of their business, medical device manufacturers and suppliers have been and are subject regularly to inquiries, investigations and audits by federal and state agencies that oversee these laws and regulations. Recent federal and state legislation has greatly increased funding for investigations and enforcement actions, which have increased dramatically over the past several years. This trend is expected to continue. Private enforcement of healthcare fraud also has increased, due in large part to amendments to the Civil False Claims Act in 1986 that were designed to encourage private persons to sue on behalf of the government. These whistleblower suits by private persons, known as qui tam relaters, may be filed by almost anyone, including physicians and their employees and patients, our employees, and even competitors. The Health Insurance Portability and Accountability Act of 1996 (HIPAA”), in addition to its privacy provisions, created a series of new healthcare-related crimes.

19

Our reliance on the activities of our non-employee consultants, whose activities are not wholly within our control, may lead to delays in the development of proposed products or in the development of our business. We rely extensively upon and have relationships with consultants. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We have limited control over the activities of these consultants and, except as otherwise required by our collaboration and consulting agreements to the extent they exist, can expect only limited amounts of their time to be dedicated to our activities.

Our Proposed Additional Operations, should they be realized, also involve significant risks. The Company has been investigating several acquisitions in other related industries. All of the proposed targets are profitable and generate cash flow. The Company has entered into a non-binding letter of intent with one acquisition target but has not entered into any definitive binding agreements to acquire any target. Even if we are successful in acquiring a target, no assurance can be given that we would be able to operate such a company profitably. Present management has no experience in operating a construction company and the construction industry has its own set of risks.

Risks Related to Common Stock

“Penny Stock” rules may make buying or selling our common stock difficult. Limitations upon Broker-Dealers Effecting Transactions in “Penny Stocks.” Trading in our common stock will likely be subject to material limitations as a consequence of regulations which limit the activities of broker-dealers effecting transactions in “penny stocks.” Pursuant to Rule 3a51-1 under the Exchange Act, our common stock is a “penny stock” because it (i) is not listed on any national securities exchange or The NASDAQ Stock Market™, (ii) has a market price of less than $5.00 per share, and (iii) its issuer (the Company) has net tangible assets less than $2,000,000 (if the issuer has been in business for at least three (3) years) or $5,000,000 (if the issuer has been in business for less than three (3) years).

Rule 15g-9 promulgated under the Exchange Act imposes limitations upon trading activities on “penny stocks”, which makes selling our common stock more difficult compared to selling securities which are not “penny stocks.” Rule 15a-9 restricts the solicitation of sales of “penny stocks” by broker-dealers unless the broker first (i) obtains from the purchaser information concerning his financial situation, investment experience and investment objectives, (ii) reasonably determines that the purchaser has sufficient knowledge and experience in financial matters that the person is capable of evaluating the risks of investing in “penny stocks”, and (iii) delivers and receives back from the purchaser a manually signed written statement acknowledging the purchaser’s investment experience and financial sophistication.

Rules 15g-2 through 15g-6 promulgated under the Exchange Act require broker-dealers who engage in transactions in “penny stocks” first to provide their customers with a series of disclosures and documents, including (i) a standardized risk disclosure document identifying the risks inherent in investing in “penny stocks”, (ii) all compensation received by the broker-dealer in connection with the transaction, (iii) current quotation prices and other relevant market data, and (iv) monthly account statements reflecting the fair market value of the securities.

There can be no assurance that any broker-dealer which initiates quotations for the Common Stock will continue to do so, and the loss of any such broker-dealer likely would have a material adverse effect on the market price of our common stock.

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock. In addition to the “penny stock” rules described below, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculatively low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

Because our common stock is deemed a low-priced “penny stock,” it will be cumbersome for brokers and dealers to trade in our common stock, making the market for our common stock less liquid and negatively affect the price of our stock.

20

We will be subject to certain provisions of the Securities Exchange Act of 1934 (the “Exchange Act”), commonly referred to as the “penny stock” rules as defined in Rule 3a51-1. A penny stock is generally defined as any equity security that has a market price less than $5.00 per share, subject to certain exceptions. Since our stock is deemed to be a penny stock, trading is subject to additional sales practice requirements of broker-dealers. These require a broker dealer to:

·Deliver to the customer, and obtain written receipts for, a disclosure document; 

·Disclose certain price information about the stock; 

·Disclose the amount of compensation received by the broker-dealer or any associated person of the broker-dealer; 

·Send monthly statements to customers with market and price information about the penny stock; and 

·In some circumstances, approve the purchaser’s account under certain standards and deliver written statements to the customer with information specified in the rules. 

Consequently, penny stock rules and FINRA rules may restrict the ability or willingness of broker-dealers to trade and/or maintain a market in our common stock. Also, prospective investors may not want to get involved with the additional administrative requirements, which may have a material adverse effect on the trading of our shares.

We Have Paid No Dividends. We have never paid any dividends on our common stock, and we do not intend to pay any dividends in the foreseeable future.

We may allocate the net proceeds from this offering in ways which differ from our estimates based on our current plans and assumptions discussed in the section titled “Use of Proceeds” and with which you may not agree. The allocation of net proceeds of the offering set forth in the “Use of Proceeds” section below represents our estimates based upon our current plans and assumptions regarding industry and general economic conditions, our future revenues and expenditures. The amounts and timing of our actual expenditure will depend on numerous factors, including market conditions, cash generated by our operations, business developments and related rate of growth. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes. Circumstances that may give rise to a change in the use of proceeds and the alternate purposes for which the proceeds may be used are discussed in the section entitled “Use of Proceeds” below. You may not have an opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use our proceeds. As a result, you and other shareholders may not agree with our decisions. See “Use of Proceeds” for additional information.

Management will have substantial discretion over the use of the proceeds of this Offering and may not choose to use it effectively. We plan to use the proceeds from this Offering as set forth in the section entitled “Use of Proceeds.” Our management will have significant flexibility in applying the net proceeds of this Offering and may apply the proceeds in ways with which you do not agree. The failure of our management to apply these funds effectively could materially harm our business.

Limitations on director and officer liability and indemnification of our officers and directors by us may discourage stockholders from bringing suit against a director. Blockhold’s Articles of Incorporation and Bylaws provide, with certain exceptions as permitted by governing state law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions.

The term “dilution” refers to the reduction (as a percentage of the aggregate Shares outstanding) that occurs for any given share of stock when additional Shares are issued. If all the Shares in this offer are fully subscribed and sold, the remaining Shares offered herein will constitute approximately 34.45% of the total Shares of stock of the Company. The Company anticipates that subsequent to this offering the Company may require additional capital or issue Shares of Stock in consideration of services rendered to the Company and such capital may take the form of Common Stock, other stock or securities or debt convertible into stock. Such future fundraising will further dilute the percentage ownership of the Shares sold herein in the Company. The dilution table below is based on the Company’s balance sheet dated September 30, 2025. The total shares outstanding assumes exercise of all outstanding options.

If you invest in our Common Stock, your interest will be diluted immediately to the extent of the difference between the offering price per share of our Common Stock and the pro forma net tangible book value per share of our Common Stock after this offering. The table below is based off an offering price of $1.50 per share.

21

Ownership Dilution

Investment Dilution

Dilution in net tangible book value per share to purchasers of our common stock in this offering represents the difference between the amount per share paid by purchasers of the Shares in this offering and the net tangible book value per share immediately after completion of this offering. In this offering, dilution is attributable primarily to our negative net tangible book value per share.

If you purchase Shares in this offering, your investment will be diluted to the extent of the difference between your purchase price per Offered Share and the net tangible book value of our common stock after this offering. Our net tangible book value as of September 30, 2025, was $(799,326) (unaudited), or $(.1186) per share. Net tangible book value per share is equal to total assets minus the sum of total liabilities and intangible assets divided by the total number of shares outstanding.

Without giving effect to issuances of shares of common stock after September 30, 2025, the table above illustrates the dilution to purchasers of Remaining Shares in this offering, on a pro forma basis, assuming 100%, 75%, 50% and 25% of the Remaining Shares are sold.

In General

Our company is offering a maximum of 3,500,000 Shares, on a best-efforts basis, at $1.50 per share. Any funds derived from this offer will be immediately available to us for our use in accordance with the uses set forth in the Use of Proceeds section of this Offering Circular. No funds will be placed in an escrow account during the offering period and no funds will be returned, once an investor’s subscription agreement has been accepted by us. There will be no refunds. This offering will terminate at the earliest of (a) the date on which the maximum offering has been sold, (b) the date which is one year from this offering being qualified by the SEC or (c) the date on which this offering is earlier terminated by us, in our sole discretion.

We intend to sell the Shares in this offering through the efforts of our officers and directors. The officers and directors will not receive any compensation for offering or selling the Shares.

Procedures for Subscribing

If you are interested in subscribing for Shares in this offering, please submit a request for information by e-mail to our CEO, Mr. Bryan Luce at: bryan@telecareholdings.com; all relevant information will be delivered to you by return e-mail.

Thereafter, should you decide to subscribe for Shares, you are required to follow the procedures described therein, which are:

·Electronically execute and deliver to us a subscription agreement; and 

·Deliver funds directly by check or by wire or electronic funds transfer via ACH to our specified bank account. 

22

Right to Reject Subscriptions. After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to us, we have the right to review and accept or reject your subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected subscriptions immediately to you, without interest or deduction.

Acceptance of Subscriptions. Upon our acceptance of a subscription agreement, we will countersign the subscription agreement and issue the Shares subscribed. Once you submit the subscription agreement and it is accepted, you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable.

This Form 1-A will be furnished to prospective investors upon their request via electronic PDF format and will be available for viewing and download 24 hours per day, 7 days per week on our company’s page on the SEC’s website: www.sec.gov.

An investor will become a shareholder of our company, and the Shares will be issued, as of the date of settlement. Settlement will not occur until an investor’s funds have cleared and we accept the investor as a shareholder.

By executing the subscription agreement and paying the total purchase price for the Shares subscribed, each investor agrees to accept the terms of the subscription agreement and attests that the investor meets certain minimum financial standards. (See State Qualification and Investor Suitability Standards below).

An approved trustee must process and forward to us subscriptions made through IRAs, Keogh plans and 401(k) plans. In the case of investments through IRAs, Keogh plans and 401(k) plans, we will send the confirmation and notice of our acceptance to the trustee.

Minimum Purchase Requirements

You must initially purchase at least $10,000 of the Shares in this offering. If you have satisfied the minimum purchase requirement, any additional purchase must be in the amount of at least $5,000.

State Law Exemption and Offerings to Qualified Purchasers

State Law Exemption. This Form 1-A does not constitute an offer to sell or the solicitation of an offer to purchase any Shares in any jurisdiction in which, or to any person to whom, it would be unlawful to do so. An investment in the Shares involves substantial risks and possible loss by investors of their entire investments. (See “Risk Factors”).

We intend to have this Offering qualified under the securities laws of Colorado, Connecticut, Delaware, Georgia, Puerto Rico and New York. However, we may, at a later date, decide to sell Shares in other states or to international investors. In the case of each state in which we sell the Shares, we will qualify the Shares for sale with the applicable state securities regulatory body, or we will sell the Shares pursuant to an exemption from registration found in the applicable state’s securities, or Blue Sky, law.

Investment Limitations

Generally, no sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural people. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A+. For general information on investing, we encourage you to refer to www.investor.gov.

Because this is a Tier 2, Regulation A+ offering, most investors must comply with the 10% limitation on investment in the Offering. The only investor in this Offering exempt from this limitation is an “accredited investor” as defined under Rule 501 of Regulation D under the Securities Act. If you meet one of the following tests you should qualify as an accredited investor:

i.You are a natural person who has had an individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years and have a reasonable expectation of reaching the same income level in the current year. 

23

ii.You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase Shares (please see below on how to calculate your net worth); 

iii.You are an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer. 

iv.You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Shares, with total assets in excess of $5,000,000. 

v.You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940 (Investment Company Act), or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940; 

vi.You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor. 

vii.You are a trust with total assets in excess of $5,000,000, your purchase of Shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the Shares; or 

viii.You are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000. 

Issuance of Shares

Upon settlement, that is, at such time as an investor’s funds have cleared and we have accepted an investor’s subscription agreement, we will either issue such investor’s purchased Shares in book-entry form or issue a certificate or certificates representing such investor’s purchased Shares.

Transferability of the Shares

The Shares will be generally freely transferable, subject to any restrictions imposed by applicable securities laws or regulations.

Advertising, Sales and Other Promotional Materials

In addition to this Form 1-A, subject to limitations imposed by applicable securities laws, we expect to use additional advertising, sales and other promotional materials in connection with this offering. These materials may include information relating to this offering, articles and publications concerning industries relevant to our business operations or public advertisements and audio-visual materials, in each case only as authorized by us. In addition, the sales material may contain certain quotes from various publications without obtaining the consent of the author or the publication for use of the quoted material in the sales material. Although these materials will not contain information in conflict with the information provided by this Form 1-A and will be prepared with a view to presenting a balanced discussion of risk and reward with respect to the Shares, these materials will not give a complete understanding of our company, this offering or the Shares and are not to be considered part of this FORM 1-A. This offering is made only by means of this Form 1-A and prospective investors must read and rely on the information provided in this Form 1-A in connection with their decision to invest in the Shares.

We are offering up to 3,500,000 shares of our Common Stock for a total of up to $5,250,000 in gross offering proceeds, assuming all securities are sold at the maximum offering price. There is a $10,000 minimum investment established for investors and no minimum Offering amount. We may sell significantly fewer shares of common stock than those

24

offered hereby. All accepted subscription funds will be immediately available for our use. We may, in our sole discretion, choose to accept the cancelation of debt owed by us as consideration for shares of common stock offered hereby. Any shares of Common Stock sold for debt cancellation shall be subject to the same terms and conditions as other shares sold hereunder, including the purchase price for such shares.

All subscription agreements and checks are irrevocable until accepted or rejected by the Company and should be delivered to us at the address provided in the subscription agreement. A subscription agreement executed by a subscriber is not binding on us until it is accepted on our behalf by our CEO or by specific resolution of our Board of Directors. We may accept or reject any subscription, in whole or in part, in its sole discretion.

We will deliver stock certificates to the purchasers within five days from request by a shareholder; otherwise, shareholders’ shares may be noted and held in our corporate shareholder register.

The Use of Proceeds is an estimate based on the Company’s current business plan. A portion of the proceeds from this Offering may ultimately be used to compensate or otherwise make payments to officers or directors of the Company. The officers and directors of the Company may be paid salaries and receive benefits that are commensurate with similar companies, and a portion of the proceeds may be used to pay these ongoing business expenses.

The Company reserves the right to change the use of proceeds set out herein based on the needs of the ongoing business of the Company and the discretion of the Company’s management. The Company may reallocate the estimated use of proceeds among the various categories or for other uses if management deems such a reallocation to be appropriate. Until sufficient funds are raised by the Company to sufficiently fund research activities, management may utilize some or all of the funds from this Offering for further capital raising efforts, rather than as set out in this Use of Proceeds section of the Offering Circular.

The Company has attempted to identify, in context, certain of the factors it currently believes may cause actual future experience and results to differ from its current expectations. The differences may be caused by a variety of factors, including but not limited to adverse economic conditions, lack of market acceptance, reduction of consumer demand, unexpected costs and operating deficits, lower sales and revenues than forecast, loss of suppliers, loss of service contracts, price increases of supplies and materials, inadequate capital, inability to raise capital or financing, the risk of litigation, loss of government licenses and permits or failure to obtain them, higher than anticipated labor costs, unanticipated expenses or losses, adverse publicity and news coverage, loss of key executives, inflationary factors, and other specific risks that may be referred to in this Offering Circular or in other reports issued by us or by third-party publishers.

The short-term goal for Blockhold is to properly capitalize, market its products and services and seek other business opportunities that would complement its current business activities in the most efficient way possible. To achieve the next phase of the Blockhold Business Plan, Blockhold plans to deploy capital raised in this Offering as follows:

(1)The fees are associated with the raising and management of the Regulation A offering. This amount primarily includes legal and auditing expenses. 

25

Overview

BlockHold Capital Corporation (Blockhold Herein) Inc. is a (i) developer and seller of medical-related technologies and care products, and (ii) dynamic and diversified Venture Development and Holding Company. Blockhold aims to create long-term value for its shareholders by expanding its offering of medical-related technologies and care products while also strategically managing a diverse portfolio of companies across various industries.

BlockHold, as a parent holding company, provides a unique opportunity for diversification. By investing in multiple Portfolio and subsidiary companies across different industries and sectors, the parent company spreads its risk and reduces its exposure to any single business or market. This diversification can help to mitigate volatility and protect the overall investment portfolio.  BlockHold Capital Corporation can leverage the synergies and cross-selling opportunities among its subsidiaries as well as connecting existing companies to innovation. By fostering innovation, collaboration, sharing resources, knowledge, and expertise across different businesses, BlockHold Capital will unlock value and create competitive advantages other entities, such as Private Equity and Venture Capital cannot. We believe this will lead to increased revenue generation, cost efficiencies, accelerated growth and ultimately, shareholder returns.

Overview of the investment strategy

As a parent holding company, Blockhold Capital actively manages its portfolio of subsidiary companies. It continually assesses the performance of each platform and subsidiary, identifies opportunities for growth or divestment, and makes strategic investment decisions accordingly. This active portfolio management approach helps the Blockhold Capital optimize its investment allocation and maximize returns.

As a venture development company, we help facilitate the entire life cycle of growth. Growth comes in three formats. Accretive growth, innovative growth and organic growth.  It is our philosophy that treating each portfolio of companies holistically, looking at all components of growth will generate a more consistent return over the life cycle of the portfolio.  We believe the blending of innovation as well as the time-tested structure of a holding company will generate strong risk-mitigated returns for our shareholders.

BlockHold board and executive staff possess a wealth of experience, industry knowledge, and managerial expertise. We provide guidance, support, and resources to our subsidiary companies, helping them navigate challenges, implement best practices, and drive growth. This value-added expertise enhances the overall performance of the portfolio and boosts Blockhold’s investment returns.

Corporate History

Our predecessor company, Moms Online, Inc. was incorporated in December 2010 in Nevada. The Company changed its name to Blockhold Capital Corporation on April 17, 2018.

Acquisition of Virtual Clinic LLC and Blue Sky Home Partners, LLC

The Company acquired two companies on July 1, 2021, Virtual Clinic, LLC and Blue Sky, LLC. The Company originally issued 850,000 shares of its common stock valued at $.50 per share. The acquisition of Blue Sky, LLC was rescinded on June 30, 2022, and has been reversed as the transaction never occurred. The shares issued of 250,000 have been cancelled and returned to the treasury of the Company. With respect to the Virtual Clinic, LLC acquisition, the purchase price was allocated to the identifiable assets and liabilities acquired, with the residual recorded as goodwill; however, as reflected in the FY24 audited financial statements, on October 9, 2024, 420,000 shares were cancelled due to representations made by the acquiree, resulting in a $210,000 reversal of previously recognized goodwill and immediately impaired and a corresponding adjustment to retained earnings. The Company has entered into the business of Tele-Health and Home Healthcare.

The Company through a consulting agreement acquired a distributor contract to enter into the Wound Care business for 580,000 shares. This consulting contract was terminated on March 24, 2023, with the return to treasury of the 580,000 shares and a payment by the Company of $11,000 to the selling party of the contract.

26

A new chapter

The first quarter of 2023 for the company recognized some significant changes. The company on boarded a new president and a new board of directors. The current structure of the board and management team brings together a combination of innovative merger and acquisition advisory experience as well as operations.

As of the beginning of  May 2023 we have launched our new wound care company – Sanologics, Inc., as a Wyoming based C-corp. The root name – Sano, is Latin, meaning “To Heal”.  We have negotiated nationwide distribution agreements with two distribution companies that will allow us to offer up to seven different amniotic treatments as well as setting up multiple distribution agreements with clinical providers.  We are also developing a “wound care in a box” program for the same clinicians, details to be announced shortly.  Currently we have 3 service providers under agreement for Sanologics. We anticipate boarding revenue by the first quarter of 2026. The unwinding of the Wound Biologics agreement has had a negative impact on our anticipated cash flow for the fiscal year of 2023. However, we are aggressively working with our existing database of clinicians and anticipate the first half of 2026 will rebound to bring the current holdings into positive EBITDA.

Simultaneously with the development of Sanologics, Inc, we are in the initial due diligence phase for launching our nationwide allergy program. This development is taking slightly longer as we have to develop a PE friendly, nationwide program with physicians and / or licensed clinicians.  The allergy division will run through the virtual clinic platform. As of this time we are still getting legal opinions about whether to form a new company or run this revenue stream through the virtual clinic platform.  The development of a PE friendly program will open up a broad range of growth opportunities for the telecare division nationally.

The virtual clinic platform, under new guidance, has onboarded 10 new clients per month, and increased revenue per month by over 20%. Management has reorganized and restructured acquisition agreements, renegotiated debt instruments, and is rapidly moving the company towards profitability.  Currently the company is operating on a 24% compound annual growth rate (“CAGR”).

Market Analysis – Virtual Healthcare portfolio

The virtual healthcare market has been expanding rapidly and is expected to reach a substantial market size. According to a recent report, the global virtual healthcare market size is projected to reach $31.78 billion by 2023, growing at a CAGR of 23.27% during the forecast period (2018-2023).

The virtual healthcare market has experienced significant growth and transformation in recent years, driven by advancements in technology, increasing demand for remote healthcare services, and the need for accessible and convenient healthcare solutions. For the telecare division the thesis is driven by the expansion of the virtual healthcare segment.  Currently with virtual clinic as the initial acquisition in the portfolio and the analysis of the company’s data sets show a strong alignment towards health maintenance as well as the diabetic sector strategy.  We believe the following segments show the strongest accretive and organic growth opportunities for the Telecare division.

Telemedicine:

Telemedicine is a key component of virtual healthcare, enabling remote consultations and diagnosis through video calls, phone calls, or online messaging. The COVID-19 pandemic has accelerated the adoption of telemedicine significantly. According to a report by McKinsey, in the United States, the number of telehealth visits increased by 154% in March 2020 compared to the previous year.

Remote patient monitoring:

Remote patient monitoring allows healthcare providers to monitor patients’ vital signs and health data remotely, enhancing the management of chronic diseases and post-surgical care. The global remote patient monitoring market is projected to reach $1.98 billion by 2025, growing at a CAGR of 13.5% from 2020 to 2025, according to a report by Grand View Research.

Digital Health Apps:

The availability of healthcare-related mobile applications has surged, providing users with access to various virtual healthcare services, such as symptom checkers, medication reminders, and fitness tracking. As of 2020, there were

27

over 325,000 mobile health apps available on major app stores worldwide, as reported by the IQVIA Institute for Human Data Science.

Remote Pharmacies and Prescription Delivery:

Virtual healthcare includes remote pharmacy services and prescription delivery, enabling patients to receive medications conveniently. The global tele pharmacy market is anticipated to reach $9.3 billion by 2028, growing at a CAGR of 16.1% from 2021 to 2028, according to a report by Grand View Research.  The development of our national PE friendly partnership is significant in the deployment and development of this sector.

Wound Care:

Market Size: In 2020, the global diabetic wound care market was valued at approximately USD 8.6 billion. It is expected to experience significant growth over the coming years.  The market has been growing at a compound annual growth rate (CAGR) of around 6% to 7% from 2017 to 2020. It is projected to maintain a similar growth rate in the foreseeable future. Diabetic foot and leg ulcers (DFUs) are one of the most common types of diabetic wounds. They account for a significant share of the market, as they often require advanced wound care products and therapies.  These therapies represent the key offerings for Sanologics.

These statistics highlight the growing importance and potential of the virtual healthcare market, driven by technological advancements and the increasing need for accessible and convenient healthcare services.  BlockHold’s Telecare division will Be well poised for growth in this sector keeping in alignment with our venture development and holding company thesis we are able to connect with early-stage technologies with a TRL level of 8 or greater as well as numerous SMB enterprises who are seeking to grow and need a capital partner with a greater vision.

Data: Simultaneously with growing these companies, the key driver behind the integration and consolidation of these entities will be the capture of significant key data sets. The alignment of each of the portfolio entities data sets will provide significant opportunities for monetization, research and development for our portfolio companies, which will also lead to interest by the larger syndicated corporations already publicly traded. By targeting the lower middle market sectors, we believe there is a significant opportunity to capture multiple datasets that may lead to significant valuation increases of the portfolio companies.

Competitive landscape analysis:

Healthcare is one of the largest and judiciary sectors in North America, Dominated by multiple conglomerate companies such as united healthcare, Teledoc and many others.   As companies have grown larger through multiple acquisitions come on it is our opinion that they are losing focus and what is truly innovative and simultaneously profitable. Health care has become regionalized, and these smaller markets and rural communities are underserved. We believe this allows is a competitive advantage. Our core offerings can be bundled together to help increase the revenue of small medical practices while simultaneously increasing profitability and offering them a pathway towards greater growth.

It’s important to note that the competitive landscape in the telemedicine industry is constantly evolving, and new players may emerge while existing ones continue to innovate. Additionally, regional and niche-focused telemedicine companies exist, targeting specific geographic areas or specialized healthcare services.  We believe that these regional players are our key pathway towards long-term sustainable growth while generating significant returns for our investors.

Investment Thesis Drivers:

The key drivers for our investment thesis are the three main components of growth: accretive, organic, innovative.  Blockhold seeks to discover and explore the synergies in business operations and data that support the growth of our existing companies as well as our client companies. Acquiring new customers, products and services and cross collateralization of our company’s data will allow expedited growth across our platforms.

Healthcare and Wellness are changing the landscape of medical practice. We believe smaller companies with specialization and market differentiation will allow us to enter segments that align with specific portfolios and gain scale at a more rapid rate than other companies seeking to grow organically.

28

Telehealth Business Development

Management believes that Telehealth, also known as telemedicine, provides Blockhold with a lucrative business opportunity for financial sales for Telehealth developers and sales professionals. The hardware segment is expected to grow at a revised CAGR of 27.3% for the next 8-year period, indicating a huge demand for telehealth equipment. Financial sales professionals can capitalize on this demand by providing financing options for telehealth equipment. This trend is expected to continue as telehealth becomes more commonplace in healthcare. Blockhold’s development of a robust telehealth platform for SofPulse Health offers significant opportunities for increased growth and revenue of the company.

Telehealth Global Healthcare Market

Telehealth is a rapidly growing field within the healthcare industry. It uses technology to provide remote medical care and consultation to patients, reducing the need for in-person visits. The telehealth market has experienced an unprecedented surge in growth as a result of the COVID-19 pandemic. According to a recent report by Reportlinker.com titled: “Global Telehealth Industry”, the global market for telehealth is projected to reach $723.3 billion by 2030, with a CAGR of 23% from 2022 to 2030. The software and services segment is expected to record a CAGR of 21.1%, reaching $462.8 billion by the end of the analysis period. The pandemic has served as a catalyst for this growth, as patients seek alternative ways to access healthcare services amid restrictions on in-person visits.

Sales and Marketing

Our prime objective is to position Blockhold as a market leader in pain management, and other aligned markets achieving estimated annualized revenues of $2.0 million by the end of 2026.

In order to achieve this objective, we have developed a compelling and disruptive marketing strategy to include:

·Direct to consumer sales 

·chiropractors, Nurse practitioners and other medical professionals working with the elderly or with diabetes patients. 

Social media is central in our communications with our targeted consumers. We have already established presence on key social media platforms such as Twitter, Facebook, Instagram and LinkedIn, to name a few.

The company will be working with a leading telemedicine partner in the US. that have the proven ability to successfully roll out the initiative and promote it to potential users.

In addition to the above, Blockhold is also either using or will be developing the following marketing programs:

·Email marketing – we will be acquiring and developing a comprehensive database of surgeons, physicians and other influential decision makers in order to maintain a communication flow about Blockhold’s companies 

·Mobile marketing/Apps – we will also maintain a communication flow through mobile phone sites and apps 

·Print marketing materials (brochures, flyers, etc.) 

·Referrals and Word-of-mouth – the positive outcomes experienced by our customers will generate significant goodwill that will permeate throughout the market 

Competition

New Product Development

Blockhold has an exhaustive pipeline of new products. These would include:

·Diabetic, pain management and other med-tech opportunities currently under evaluation and due diligence 

29

Employees

We do not have any employees but rely on consultants. We have retained approximately 9 individuals as independent contractors that are involved in management, business development and sales, research & development and administrative functions.

DESCRIPTION OF PROPERTY

We have an office location in a serviced office suite in Las Vegas, NV which we rent on a month-to-month basis. We believe such an office is adequate for our present needs.

Legal Proceedings

None

Results of Operations Nine Months Ended September 30, 2025 and 2024.

Revenue

Revenue of the Company’s Virtual Clinic product during the current period increased by $127,204.  

Revenues for sales of our Virtual Clinic product are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

We anticipate that revenue will increase in future periods as the roll out of the Wound Care products continues. The Company is looking to partner with global participants in the wound management market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, and distribution agreements for the health offerings. The Company also looks to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other diabetes related markets.

Cost of Revenue

Cost of revenue increased by $104,835 or 33.2% from the previous year to $420,282 during the current period compared to $315,447 during the previous period from its only revenue generating operations from Virtual Clinic. The cost of revenue is recognized by those sales recorded as gross, for which we are the principal in the transaction as opposed to net sales, which reflect no cost of revenue.  

It is anticipated that the cost of revenue will increase in future periods.

30

Operating Expenses

Our operating expenses increased by $35,491 to $391,118 in 2025 compared to $355,627 in 2024. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in stock-based compensation and a decrease in a contract for a web-based platform.

Other Income

The other income was $122 in 2025 compared to $256 in 2024. Other income includes interest income.

The decrease in other income during the nine months ended September 30, 2025, compared to the same period in 2024 was primarily the result of reduced interest income.

Liquidity and Capital Resources

Results of Operations Year Ended December 31, 2024 and December 31, 2023.

Revenue

Revenue of the Company’s Virtual Clinic product during the current year increased by $63,770.

31

Revenues for sales of our Virtual Clinic product are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. During the year ended December 31, 2023, the Company also recognized $129,806 in royalty/licensing revenue from a former related party.

We anticipate that revenue will increase in future periods as the roll out of the Wound Care products continues. The Company is looking to partner with global participants in the wound management market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, and distribution agreements for the health offerings. The Company also looks to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other diabetes related markets.

Cost of Revenue

Cost of revenue decreased by $5,757 or 1.33% from the previous year to $425,554 during the current year compared to $431,311 during the previous year. The cost of revenue is recognized by those sales recorded as gross, for which we are the principal in the transaction as opposed to net sales, which reflect no cost of revenue.  The Company incurred $107,939 in commission sales in 2023 from its royalty/licensing revenue.

It is anticipated that the cost of revenue will increase in future periods.

Operating Expenses

Our operating expenses increased by $161,732 to $551,047 in 2024 compared to $389,315 in 2023. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in the consulting fees, professional fees, stock based compensation and increase costs from outside providers for charges of lab costs due to the increase in sales volume.

Other Income/(Expense)

The other income/expense was $338 in 2024 compared to a loss of $10,416 in 2023. Other income/expense includes a loss on contract termination in 2023 in the amount of $11,000 and interest income.

The decrease in other expenses during our fiscal year 2023 was primarily the result of the loss on a contract termination incurred in 2023.

Liquidity and Capital Resources (audited)

32

Going Concern

We believe that our ongoing losses and lack of resources cause doubt about our ability to continue as a going concern.

Since inception and through September 30, 2025, the Company has raised in excess of two million in equity. These funds have been used to commence the operations of the Company to acquire and begin the development of its intellectual property portfolio. These activities include corporate development, acquisitions and operating costs. Our accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. The Company has incurred substantial losses since its inception. Its current liabilities exceed its current assets, and available cash is not sufficient to fund expected future operations. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from various potential marketing agreements, has engaged various private parties to raise additional capital and is seeking profitable companies. Our cash on hand on September 30, 2025, was $94,394. This will be sufficient through December 31, 2025, to fund operations if additional capital is not raised.

MANAGEMENT

The following table sets forth the name and age of officers and director. Our Executive officers are elected annually by our Board of Directors. Our executive officers hold their offices until they resign, are removed by the Board, or his successor is elected and qualified.

Biographies

Bryan Luce, President and Director. Brian is a senior business and financial executive experienced in C-Suite and corporate management, mergers & acquisitions, finance, strategic planning, turnarounds and growth strategies.  Mr. Luce has held officer-level positions in start-ups through mid-market companies.  In addition to his extensive experience in M&A, growth and turnaround strategies, Bryan is an entrepreneur, founding several start-up companies and serving as a mentor and angel investor to dozens of early-stage companies.   Mr. Luce has worked across multiple sectors, including Aviation, Bio-Tech, Clean-tech, Med-tech, Manufacturing, Plastics, Transportation & Logistics, Real Estate, Finance and Technology companies.  He is a mentor for multiple early-stage Incubators, and programs for NYSERDA, and the Clean Tech Open. Mr. Luce is Certified in lean processes, Sig-Sigma, and project management. Mr. Luce spent over ten years as a volunteer Paramedic, firefighter, EMS and CPR Instructor.

Joe Ramelli has been the Secretary and director since December 2022. Joe Ramelli, Secretary and Director. Joe is the President of Ramelli Asset Management. and is an investor and consultant providing strategic advisory services to biotech companies. Mr. Ramelli has advised CEOs on business strategies, business development, capital raising, talent acquisition, and corporate governance. Mr. Ramelli has also been a Senior Equity Analyst at EOS Funds, where he conducted extensive research on companies to evaluate investment prospects. He has also developed in-depth financial

33

models and forecasts and evaluated the competitive landscape of target companies. Mr. Ramelli also has acted as CEO of a publicly traded biotech company, where he oversaw and managed all aspects of the company while executing a successful restructuring and reorganization at the request of the company’s largest investors. Mr. Ramelli started his career at Barclays Global Investors.

Trent Gunter, MBA, has been a director since December 2022.

Trent is a financial executive with 40+ years of banking and private equity experience. He is a graduate of The Wharton School and the UCLA Anderson School of Management, where he was a Dean’s Fellow. Mr. Gunter is currently a managing partner of Helios Energy Corporation, a holding company in the renewable energy industry, and a member of the advisory board of American Battery Factory, an energy storage device company. He has held leadership and senior executive positions at Citibank, Chase Manhattan Bank (now JPMorgan Chase), Morgan Stanley, Daiwa Securities and Credit Lyonnais Securities.

Ashley Sawdaye, MBA, has been a director since March 2018.

Ashley has over 20 years of experience as a seasoned executive, entrepreneur, and investor with expertise in business operations, corporate strategy, and digital marketing. Past experiences include Head of the digital strategy for L’Oreal, Advertising.com (sold to AOL/Time Warner for $435M), and president of a digital marketing consulting firm, Galaxy Consulting, with clientele in healthcare, fintech, AI, and blockchain businesses.

Robert Schlegel has been a director since May 2016.

Bob has been active in the investment and securities industry for over 30 years. He is a Certified Financial Planner and has owned multiple investment advisory companies.

Except as set forth in our discussion below in “Certain Relationships and Related Transactions,” none of our directors or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are required to be disclosed pursuant to the rules and regulations of the Commission.

Kayur Patel, MD, Chief Medical Officer. Dr. Kayur Patel is an acclaimed national speaker on the subject of quality in healthcare.  He is a nationally renowned thought leader who has dedicated his work to improving Health Outcomes through innovation in Patient Engagement, Access to Care, and Community Leadership. Dr. Patel is an experienced physician with more than 20 years of practice and leadership roles in Internal Medicine, Emergency Medicine, and Occupational Health. His forte lies in aligning physicians and hospital leaderships for successfully converting the challenges of healthcare reforms into opportunities for the community, physicians and hospitals. A result-oriented Business & Healthcare Leader, Dr. Patel is a Fellow of the American College of Physicians, American College of Physician Executives, American College of Healthcare Executive and American College of Emergency Physicians.

Code of Ethics

We do not have a code of ethics that applies to our officers, employees and directors.

Corporate Governance

The business and affairs of the company are managed under the direction of our board. We have a board consisting of five members. In addition to the contact information in this annual report, each stockholder will be given specific information on how he/she can direct communications to the officers and our director of the corporation. All material communications from stockholders are relayed to our board.

Role in Risk Oversight

Our board is primarily responsible for overseeing our risk management processes. The board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company’s assessment of risks. The board focuses on the most significant risks facing our company and our company’s general risk management strategy, and also ensures that risks undertaken by our company are consistent with the board’s appetite for risk. While the board oversees our company’s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.

34

The following executives of the Company received compensation in the amounts set forth in the chart below for the fiscal years ending December 31, 2025 and 2024. No other item of compensation was paid to any officer or director of the Company other than reimbursement of expenses.

Summary Compensation Table

Outstanding Equity Awards at Fiscal Year-End Table

Compensation of Directors

The directors receive no compensation for serving as directors. However, the Company may reimburse its directors for any out-of-pocket cost reasonably incurred to attend a Board meeting.

Compensation Agreements

All new officers have agreed to accrue and defer payment of their compensation until the Company has generated sufficient financing proceeds or revenue to pay such compensation. Mr. Luce received compensation of $5,000 per month.

Stock Incentive Plan; Options; Equity Awards

We have not adopted any long-term incentive plan that provides compensation intended to serve as an incentive for performance.

Limitation of Liability and Indemnification of Officers and Directors

Our Bylaws limit the liability of directors and officers of the Company to the maximum extent permitted by Nevada law. The Bylaws state that the Company shall indemnify and hold harmless each person who was or is a party or is threatened to be made a party to, or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or an officer of the Company or such director or officer is or was serving at the request of the Company as a director, officer, partner, member, manager, trustee, employee or agent of another company or of a partnership, limited liability company, joint venture, trust or other enterprise.

35

The Company believes that indemnification under our Bylaws covers at least negligence and gross negligence on the part of indemnified parties. The Company also may secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our Bylaws permit such indemnification.

The Company may also enter into separate indemnification agreements with its directors and officers, in addition to the indemnification provided for in our Bylaws. These agreements, among other things, may provide that we will indemnify our directors and officers for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of such person’s services as one of our directors or officers, or rendering services at our request, to any of its subsidiaries or any other company or enterprise. We believe that these provisions and agreements are necessary to attract and retain qualified people as directors and officers.

There is no pending litigation or proceedings involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

For additional information on indemnification and limitations on the liability of our directors and officers, please review the Company’s Bylaws, which are attached to this Offering Circular.

The following table sets forth certain information regarding our shares of common stock beneficially owned as of September 30, 2025, for (i) each stockholder known to be the beneficial owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock options or warrants. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.

For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within 60 days of September 30, 2025. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of people named above, any shares that such person or person has the right to acquire within 60 days of September 30, 2025 is deemed to be outstanding but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership. Unless otherwise specified, the address of each of the people set forth below is care of the company at the address of 3226 Clark Rd., Sarasota, FL, 34231.

(1)Calvin Wong owns 903,500 shares directly and 943,894 shares through attribution by his ownership of 46.69% of IceLounge Media that owns 2,021,619 shares of the Company’s common stock. 

36

(2) Ed Wong owns 275,000 shares directly and 50,540 shares through attribution by his ownership of 2.5% of IceLounge Media that owns 2,021,619 shares of the Company’s common stock. Additionally, Ed Wong owns 66,875 shares by attribution by his ownership of 50% of WB Capital, Inc., that owns 133,750 of the Company’s common stock. Mr. Wong’s wife owns 62,500 shares of the Company’s common stock which are included for purposes of beneficial ownership. 

(3)IceLounge Media is owned and controlled by Calvin Wong. 

There are no transactions in the interest of Management or other affiliated parties of Blockhold

The Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”) authorize us to issue (a) 75,000,000 shares of Common Stock, par value $0.001 per share, of which, 6,858,974 shares are issued and outstanding as of the date of this Offering Circular, and (b) 9,300,000 shares of Preferred A Stock, $0.001 par value per share, 0 of which were issued and outstanding on September 30, 2025, and (c) 5,000,000 shares of Preferred B Stock, $0.001 par value per share, 0 of which were issued and outstanding on September 30, 2025.

Common Stock

Holders of Common Stock are entitled to one vote for each share on all matters submitted to a vote of shareholders. Holders of Common Stock do not have cumulative voting rights. Holders of Common Stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares legally available funds. In the event of our liquidation, dissolution or winding up, subject to the preferences of any shares of Preferred Stock which may then be authorized and outstanding, each outstanding share entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the Common Stock.

Holders of Common Stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the Common Stock. The rights of the holders of Common Stock are subject to any rights that may be fixed for holders of Preferred Stock, when and if any Preferred Stock is authorized and issued. All outstanding shares of Common Stock are duly authorized, validly issued, fully paid and non-assessable.

Preferred Stock

Our articles of incorporation authorized the issuance of up to 9,300,000 shares of Preferred A Stock, and up to 5,000,000 shares of Preferred B Stock in one or more series with such designations, voting powers, if any, preferences and relative, participation, optional or other special rights, and such qualifications, limitations and restrictions, as are determined by resolution of our Board of Directors.

Preferred A Stock

On February 13, 2023, the Company filed a Certificate of Designation that authorized the issuance of up to nine million, three hundred thousand (9,300,000) shares of a new series designated “Preferred A Stock,” and five million (5,000,000) shares of a new series designated “Preferred B Stock” established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Preferred Stock A shall be entitled to convert into one hundred (10) shares of Common stock.

There are no rights to dividends or liquidation preferences associated with Preferred A Stock. Currently there are no Preferred A Stock issued.

The summary of the rights, privileges and preferences of the Preferred A Stock described above is qualified in its entirety by reference to the Certificate of Designation, a copy of which is an exhibit hereto.

Preferred B Stock

37

On February 13, 2023, the Company filed a certificate of designation for 5,000,000 shares of Preferred B Stock designated as Preferred B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares. For each share of Series B, the holder, on conversion, shall receive two (2) shares of common stock. As of the date of this Prospectus, there are no Preferred B shares outstanding.

Dividend Policy

We have not declared dividends since our inception. Holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We presently anticipate that all earnings, if any, will be retained for the development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

Transfer Agent

The transfer agent for our common stock is:

Securities Transfer Corporation

2901 Dallas Pkwy, Ste #380

Plano, TX, 75093

Ph: (469) 633-0101

LEGAL MATTERS

The validity of the common stock offered by this offering circular will be passed upon for us by Jeff Turner, Esq of JDT Legal, West Jordan, Utah.

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Insofar as indemnification of liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

EXPERTS

The financial statements for the years ended December 31, 2024 and 2023, and for the nine months ended September 30, 2025 and 2024 included in this prospectus were prepared by management. The financial statements for the years ended December 31, 2024 and 2023 have been audited by Barton CPA PLLC.

WHERE YOU CAN FIND MORE INFORMATION

We have filed a registration statement on Form Registration A with the SEC for the stock offered pursuant to this prospectus. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. Statements contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and, in each instance, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. For further information with respect to us and the common stock offered hereby, please refer to the registration statement and its exhibits and schedules for further information relating to us and our common stock.

38

SIGNATURES

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woodland Hills, California on February 9, 2026.

This offering statement has been signed by the following people in the capacities and on the dates indicated.

39

TABLE OF CONTENTS

40

BLOCKHOLD CAPITAL CORPORATION

September 30, 2025 and December 31, 2024

(Unaudited)

F-1

BLOCKHOLD CAPITAL CORPORATION

(Unaudited)

F-2

BLOCKHOLD CAPITAL CORPORATION

For the Three, Six and Nine Months Ended September 30, 2025 and 2024

(Unaudited)

F-3

BLOCKHOLD CAPITAL CORPORATION

(Unaudited)